To
Trustees' Annual Report for the period
Period start date 12 December 2024
Period end date 30 September 2025
From
Section A Reference and administration details
Charity name Other names charity is known by Registered charity number (if any) 1211400
MSK Regen
Charity's principal address MSK House, London Road, Silk Willoughby, Sleaford Postcode NG34 8NY
Names of the charity trustees who manage the charity
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Trustee name | Office (if any) | Dates acted if not for whole **year ** |
Name of person (or body) entitled to appoint trustee (ifany) |
|---|---|---|---|---|
| Paul Lee | Year | |||
| SallyEdwards | Year | |||
| Tanvi Verma | Year | |||
Names of the trustees for the charity, if any, (for example, any custodian trustees)
Name Dates acted if not for whole year
March 2012
TAR
1
| Names and addresses of advisers (Optional information) Type of adviser Name Address |
Names and addresses of advisers (Optional information) Type of adviser Name Address |
Names and addresses of advisers (Optional information) Type of adviser Name Address |
|---|---|---|
Name of chief executive or names of senior staff members (Optional information)
Section B Structure, governance and management
Description of the charity’s trusts
Type of governing document Constitution
- (eg. trust deed, constitution)
How the charity is constituted Charitable Incorporated Organisation– foundation model, incorporated under (eg. trust, association, company) the Charities Act 2011.
Trustee selection methods Voting members are its charity trustees (eg. appointed by, elected by)
Additional governance issues (Optional information)
You may choose to include additional information, where relevant, about:
-
policies and procedures adopted for the induction and training of trustees;
-
the charity’s organisational structure and any wider network with which the charity works;
-
relationship with any related parties;
-
trustees’ consideration of major risks and the system and procedures to manage them.
Section C Objectives and activities
The preservation and protection of public health and the advancement of health education for the public benefit, in particular by: advancing and supporting research, training, and public awareness initiatives in musculoskeletal Summary of the objects of the regeneration, aimed at improving patient outcomes and professional knowledge charity set out in its through advanced medical treatments, rehabilitation services, and educational governing document resources.
March 2012
TAR
2
During the reporting period, MSK Regen undertook activities to preserve and protect public health and advance health education, with a particular focus on musculoskeletal regeneration, rehabilitation and improving patient outcomes. The charity’s principal activities included organising the MSK Regen Conference in London on 29 April 2025. The conference brought together clinicians, researchers, allied health professionals, patients and industry representatives to share current evidence and professional knowledge concerning musculoskeletal treatment, regenerative medicine, surgical innovation and rehabilitation. The charity also supported research directed towards improving the assessment, treatment and rehabilitation of musculoskeletal conditions. This included specialist gait and motion analysis and work relating to the evaluation of noninvasive and wearable therapeutic approaches. These activities were intended to advance scientific knowledge and support the development of better outcomes for patients.
Summary of the main activities undertaken for the advance scientific knowledge and support the development of better outcomes for patients. public benefit in relation to In addition, MSK Regen developed educational and public-awareness resources these objects (include within to make information about musculoskeletal health, regenerative treatments and this section the statutory rehabilitation more accessible to patients, carers, healthcare professionals and declaration that trustees have the wider public. The charity also supported patient-focused initiatives, including had regard to the guidance the Bionic Joint Community, which provides information, encouragement and issued by the Charity peer support for people living with joint replacements and other musculoskeletal Commission on public conditions. benefit) These activities were undertaken to further the charity’s objects by promoting
These activities were undertaken to further the charity’s objects by promoting research, training, professional education and public awareness in musculoskeletal regeneration. Any private benefit arising from the charity’s activities was incidental and necessary to achieving these charitable purposes. The trustees confirm that, when planning and carrying out the charity’s activities, they had regard to the Charity Commission’s guidance on public benefit.
Additional details of objectives and activities (Optional information)
You may choose to include further statements, where relevant, about:
-
policy on grantmaking;
-
policy programme related investment;
-
contribution made by volunteers.
March 2012
TAR
3
Section D Achievements and performance
This was MSK Regen’s first reporting period as a registered Charitable Summary of the main Incorporated Organisation. During this time, the charity progressed rapidly from achievements of the charity its establishment to the active delivery of research, education and patient- during the year support initiatives in musculoskeletal health, regenerative medicine and rehabilitation. The charity’s principal achievement was the successful delivery of its first MSK Regen Conference in London on 29 April 2025. The event brought together leading clinicians, researchers, allied health professionals, patients and industry partners to examine advances across the complete patient pathway—from regenerative treatments and surgical innovation to rehabilitation and long-term recovery. By placing scientific evidence, clinical experience and the patient perspective within the same multidisciplinary programme, the conference encouraged meaningful professional discussion and collaboration. It also strengthened the relationships required to support the charity’s future research and educational programmes and established MSK Regen as an emerging convenor within the musculoskeletal regeneration community. Beyond the conference, the charity made important progress across its three principal areas of work. In education, it developed accessible, evidence-based resources to help patients, carers and healthcare professionals understand developments in musculoskeletal regeneration, treatment and recovery. In community support, it advanced patient-focused initiatives, including the Bionic Joint Community, which provides information, encouragement and peer connection for people living with joint replacements and other musculoskeletal conditions. In research, MSK Regen supported work intended to improve the objective assessment, treatment and rehabilitation of musculoskeletal conditions. This included the specialist gait and motion analysis supporting the evaluation of innovative, non-invasive and wearable rehabilitation approaches. This work helped establish a foundation for producing clinically relevant evidence capable of improving both professional knowledge and patient care. Taken together, these achievements represent a strong and purposeful beginning for MSK Regen. The charity established a multidisciplinary platform connecting research, clinical practice, education and lived patient experience, while creating the foundations from which its public-benefit activities can continue to grow.
March 2012
TAR
4
Section E Financial review
Brief statement of the charity’s policy on reserves
As a newly established charity, MSK Regen has not yet adopted a formal reserves target. The trustees intend to set a reserves policy during the next period as income and expenditure patterns become established. At 30 September 2025 the charity held free reserves (unrestricted funds) of £200.
Details of any funds materially None. All of the charity's funds were unrestricted and in surplus. The charity held in deficit unrestricted cash funds of £200 at the end of the period.
Further financial review details (Optional information)
You may choose to include additional information, where relevant about:
-
the charity’s principal sources of funds (including any fundraising);
-
how expenditure has supported the key objectives of the charity;
-
investment policy and objectives including any ethical investment policy adopted.
Section F Other optional information
Section G Declaration
The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees
Signature(s) Tanvi Full name(s) Tanvi Verma Position (eg Secretary, Chair, Trustee etc) Date 27/07/2026
March 2012
TAR
5
MSK Regen · Registered Charity No. 1211400
MSK REGEN
Charitable Incorporated Organisation
Trustees' Annual Report and
Financial Statements
For the period 12 December 2024 to 30 September 2025 Registered Charity Number: 1211400
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 1
MSK Regen · Registered Charity No. 1211400
Administrative details
| Administrative details | |
|---|---|
| Charity name | MSK Regen |
| Other name used | MSK Regen Foundation |
| Registered charity number | 1211400 |
| Legal structure | Charitable Incorporated Organisation (CIO) — foundation model |
| Governing document | CIO constitution (Charity Commission foundation model), adopted 9 December 2024 |
| Principal office | MSK House, London Road, Silk Willoughby, Sleaford |
| Trustees | Prof Paul Y. F. Lee; Sally Edwards; Tanvi Verma |
| Bankers | Lloyds Bank plc |
| Contact | tech@mskregen.co.uk · mskregen.co.uk |
The trustees named above served throughout the reporting period. The charity's trustees are also its only voting members, as provided for by the foundation model constitution.
Structure, governance and management
Governing document and legal structure
MSK Regen is a Charitable Incorporated Organisation (CIO) established under the Charities Act 2011 and registered with the Charity Commission for England and Wales (number 1211400). It is governed by a constitution based on the Charity Commission's foundation model, adopted on 9 December 2024. As a CIO, the charity is an incorporated body able to hold property, employ staff and enter into contracts in its own name.
Under the foundation model, the charity's only voting members are its charity trustees. This gives the charity a small, single-tier governance structure in which the trustees are collectively responsible for direction, decision-making and control.
Decision-making and risk
The trustees meet as required to set the charity's strategy, approve expenditure and monitor its financial position. Day-to-day scientific and educational direction is informed by a Scientific Advisory Committee whose members bring expertise in orthopaedics, regenerative medicine and histology. As this is the charity's first reporting period, the trustees have focused on establishing sound financial controls, including operating a single charity bank account with Lloyds Bank and reviewing all receipts and payments. The trustees consider the principal risk in the period to have been reliance on a small number of income sources, which they intend to broaden as the charity develops.
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 2
MSK Regen · Registered Charity No. 1211400
Objects and activities
Charitable objects
The object of the CIO, as set out in its constitution, is:
“The preservation and protection of public health and the advancement of health education for the public benefit, in particular by: Advancing and supporting research, training, and public awareness initiatives in musculoskeletal regeneration, aimed at improving patient outcomes and professional knowledge through advanced medical treatments, rehabilitation services, and educational resources.”
Public benefit statement
The trustees confirm that they have had regard to the Charity Commission's guidance on public benefit when planning the charity's activities and setting its priorities for the period. The charity's work benefits the public by advancing knowledge and education in musculoskeletal health and regenerative medicine, by supporting research that seeks to improve patient outcomes, and by making information and support available to patients and the wider community. The benefits are open to the public and any private benefit arising is incidental to carrying out the charitable purposes.
Activities in the period
MSK Regen pursues its object through three main areas of activity:
-
Education — developing accessible resources, workshops and public information about musculoskeletal health, recovery and regenerative medicine, so that patients and professionals can better understand and act on emerging evidence.
-
Community support — patient-led initiatives, including the Bionic Joint Community, which supports people living with knee or hip replacements and others navigating musculoskeletal conditions.
-
Research — supporting clinical studies that advance musculoskeletal regeneration, including work relating to the Achilles Tendinopathy Study, which evaluates non-invasive, wearable therapy approaches.
Achievements and performance
The period under review was MSK Regen's first as a registered Charitable Incorporated Organisation, and the trustees are proud of the ambition and pace with which the charity established itself and began delivering on its mission to advance musculoskeletal health, regenerative medicine and rehabilitation for the public benefit. During the nine months to 30 September 2025 the charity moved quickly from formation to active delivery across its education, community and research aims, while putting in place the governance and financial foundations for sustainable growth.
Flagship MSK Regen Conference
The standout achievement of the period was the delivery of the charity's flagship MSK Regen Conference, held in London on 29 April 2025. Conceived as a landmark gathering for the musculoskeletal field, the conference brought together leading clinicians, researchers, allied health professionals, patients and industry partners to share the latest evidence, exchange ideas and build new collaborations. The programme spanned the full patient journey — from advances in regenerative treatment and surgical
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 3
MSK Regen · Registered Charity No. 1211400
innovation through to rehabilitation and long-term recovery — and created a rare, cross-disciplinary forum in which academic insight, frontline clinical experience and the patient voice were given equal weight.
Education and public awareness
MSK Regen continued to develop accessible, evidence-based resources that translate complex advances in musculoskeletal regeneration into information that patients, carers and professionals can understand and act upon. By raising awareness and improving the quality of decision-making about treatment and recovery, this work extends the reach of the charity's public benefit well beyond those it meets directly.
Community and patient support
The charity advanced its patient-led initiatives, including the Bionic Joint Community, which offers information, encouragement and peer connection to people living with knee and hip replacements and other musculoskeletal conditions. Placing lived experience at the centre of the charity's work ensures that its education and research remain firmly grounded in the priorities of the people it exists to serve.
Research
In support of its research aims, MSK Regen backed studies directed at improving patient outcomes. This advances both patient care and professional knowledge, and reflects the charity's commitment to funding work that has practical benefit for patients.
Building strong foundations
The trustees are grateful to everyone who supported the charity in its first year, including the generosity of individual donors. Taken together, these achievements represent a strong and purposeful start. The trustees confirm that all of the charity's activities during the period were carried out in furtherance of its charitable objects and for the public benefit, and they consider the charity to be well placed to build on this momentum in the year ahead.
Financial review
The results for the period are set out in the financial statements on the following pages. Total receipts were £9,200.00 , total payments were £9,000.00 , and the charity recorded a net surplus of £200.00 . The charity held cash funds of £200.00 at 30 September 2025, all of which are unrestricted.
Principal funding sources
The charity's income in the period came from donations from organisations and individuals supportive of its aims, together with a significant donation from a trustee. The trustees are grateful to all those who supported the charity during its first period of operation. Further detail is given in the notes to the accounts.
Reserves policy
The trustees recognise the importance of holding sufficient reserves to allow the charity to meet its commitments and continue its work. As the charity is newly established, a formal reserves target has not yet been set; the trustees intend to adopt a reserves policy during the next period as income and expenditure patterns become clearer. At 30 September 2025 the charity held free reserves of £200.
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 4
MSK Regen · Registered Charity No. 1211400
Plans for future periods
In the next period the trustees intend to build on the foundations established during 2025 by: broadening the charity's income base beyond its initial supporters; expanding its educational resources and publicawareness activities in musculoskeletal health; growing the Bionic Joint Community and other patientsupport initiatives; and continuing to support research into musculoskeletal regeneration and rehabilitation. The trustees will also formalise the charity's reserves and risk-management policies as its activities grow.
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 5
MSK Regen · Registered Charity No. 1211400
Receipts and payments accounts
For the period 12 December 2024 to 30 September 2025 · prepared on the receipts and payments basis using the Charity Commission pro forma (CC16a).
| Unrestricted funds £ |
Restricted funds £ |
Endowment funds £ |
Total funds £ | Last year £ | |
|---|---|---|---|---|---|
| A1 Receipts | |||||
| Donations, grants and sponsorship | 2,200 | – | – | 2,200 | – |
| Donation from trustee (Prof P Y F Lee) |
7,000 | – | – | 7,000 | – |
| Sub total (gross income for AR) | 9,200 | – | – | 9,200 | – |
| A2 Asset and investment sales | |||||
| Sub total | – | – | – | – | – |
| Total receipts | 9,200 | – | – | 9,200 | – |
| A3 Payments | |||||
| Charitable activities – research | 9,000 | – | – | 9,000 | – |
| Sub total | 9,000 | – | – | 9,000 | – |
| A4 Asset and investment purchases |
|||||
| Sub total | – | – | – | – | – |
| Total payments | 9,000 | – | – | 9,000 | – |
| Net of receipts / (payments) | 200 | – | – | 200 | – |
| A5 Transfers between funds | – | – | – | – | – |
| A6 Cash funds last year end | – | – | – | – | – |
| Cash funds this year end | 200 | – | – | 200 | – |
All funds are unrestricted; the charity held no restricted or endowment funds. There are no prior-year comparatives, this being the charity's first accounting period. Figures are rounded to the nearest £.
Statement of assets and liabilities
As at 30 September 2025
| Category / details | Unrestricted funds £ | Restricted funds £ | Endowment funds £ |
|---|---|---|---|
| B1 Cash funds | |||
| Lloyds Bank current account | 200 | – | – |
| Total cash funds | 200 | – | – |
| B2 Other monetary assets — none held | – | – | – |
| B3 Investment assets — none held | – | – | – |
| B4 Assets retained for the charity’s own use — none held | – | – | – |
| B5 Liabilities — none | – | – | – |
The total cash funds shown above agree to the cash funds carried forward in the receipts and payments account.
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 6
MSK Regen · Registered Charity No. 1211400
Notes to the accounts
Basis of preparation
These accounts have been prepared on the receipts and payments basis in accordance with the Charities Act 2011. They summarise the money actually received and paid during the period, and the charity's assets and liabilities at the period end. They do not reflect amounts owed to or by the charity, or nonmonetary resources. All figures are stated in pounds sterling (GBP). The accounts have been prepared from the charity's Lloyds Bank statements for the period.
| Source | Date | Amount £ |
|---|---|---|
| IBSA Pharma Ltd | 15 Apr 2025 | £1,000.00 |
| United Orthopaedic | 6 May 2025 | £1,200.00 |
| Donation — Prof Paul Y. F. Lee (trustee) | 23 Jun 2025 | £7,000.00 |
| Total receipts | £9,200.00 |
| Payee / reference | Date | Amount £ |
|---|---|---|
| Gait and Motion TE | 23 Jun 2025 | £9,000.00 |
| Total payments | £9,000.00 |
This payment relates to specialist gait and motion analysis in support of the charity's research activities.
Note 3 — Cash funds
Cash funds comprise the balance held in the charity's Lloyds Bank current account. The account opened the period with a nil balance and closed at £200, reconciling to the surplus for the period.
Note 4 — Trustee remuneration and related party transactions
No trustee received any remuneration or other benefit from the charity during the period. No expenses were reimbursed to trustees. During the period the charity received a donation of £7,000 from Prof Paul Y. F. Lee, a trustee of the charity; the donation was made on the same terms as any other gift and conferred no benefit on the donor.
Note 5 — Funds
All of the charity's funds are unrestricted general funds available for its charitable purposes. The charity held no restricted or endowment funds during the period.
Trustees' Annual Report and Financial Statements · 12 December 2024 to 30 September 2025 · Page 7